ITP
MCID: THR100
MIFTS: 54

Thrombocytopenic Purpura, Autoimmune (ITP) malady

Categories: Rare diseases, Immune diseases, Blood diseases

Aliases & Classifications for Thrombocytopenic Purpura, Autoimmune

Aliases & Descriptions for Thrombocytopenic Purpura, Autoimmune:

Name: Thrombocytopenic Purpura, Autoimmune 54 56 13
Idiopathic Thrombocytopenic Purpura 12 50 29 14
Autoimmune Thrombocytopenic Purpura 12 50 14
Immune Thrombocytopenic Purpura 12 56 69
Itp 50 56
Thrombocytopenia Due to Platelet Alloimmunization 69
Purpura, Thrombocytopenic, Idiopathic 42
Thrombocytopenic Purpura Autoimmune 50
Purpura Thrombocytopenic Idiopathic 52
Primary Thrombocytopenic Purpura 12
Ideopath Thrombocytopenic Pur 12
Autoimmune Thrombocytopenia 69
Immune Thrombocytopenia 56
Idiopathic Purpura 12
Werlhof's Disease 12

Characteristics:

Orphanet epidemiological data:

56
immune thrombocytopenic purpura
Inheritance: Not applicable; Prevalence: 1-5/10000 (Europe),1-9/100000 (France); Age of onset: All ages;

HPO:

32
thrombocytopenic purpura, autoimmune:
Inheritance autosomal dominant inheritance


Classifications:



External Ids:

OMIM 54 188030
Disease Ontology 12 DOID:8924
ICD10 33 D69.3
ICD9CM 35 287.31
MeSH 42 D016553
NCIt 47 C3446
Orphanet 56 ORPHA3002
MESH via Orphanet 43 D016553
UMLS via Orphanet 70 C0398650
ICD10 via Orphanet 34 D69.3
UMLS 69 C0398650

Summaries for Thrombocytopenic Purpura, Autoimmune

NIH Rare Diseases : 50 idiopathic thrombocytopenic purpura (itp) is a bleeding disorder characterized by too few platelets in the blood. this is because platelets are being destroyed by the immune system. symptoms may include bruising, nosebleed or bleeding in the mouth, bleeding into the skin, and abnormally heavy menstruation. with treatment, the chance of remission (a symptom-free period) is good. rarely, itp may become a chronic ailment in adults and reappear, even after remission. last updated: 6/6/2016

MalaCards based summary : Thrombocytopenic Purpura, Autoimmune, also known as idiopathic thrombocytopenic purpura, is related to thrombocytopenia due to platelet alloimmunization and hemarthrosis, and has symptoms including thromboembolism, thrombocytopenia and purpura. An important gene associated with Thrombocytopenic Purpura, Autoimmune is FCGR2C (Fc Fragment Of IgG Receptor IIc (Gene/Pseudogene)), and among its related pathways/superpathways are Response to elevated platelet cytosolic Ca2+ and Cell surface interactions at the vascular wall. The drugs Amodiaquine and Artemether have been mentioned in the context of this disorder. Affiliated tissues include bone, skin and bone marrow, and related phenotypes are Decreased human papilloma virus 16 (HPV16) pseudovirus infection and hematopoietic system

Disease Ontology : 12 A primary thrombocytopenia that involves relatively few platelets in blood as a result of autoantibodies.

OMIM : 54 Autoimmune thrombocytopenic purpura is characterized by a low platelet count, normal bone marrow, and the absence of... (188030) more...

Related Diseases for Thrombocytopenic Purpura, Autoimmune

Diseases related to Thrombocytopenic Purpura, Autoimmune via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 53)
id Related Disease Score Top Affiliating Genes
1 thrombocytopenia due to platelet alloimmunization 11.6
2 hemarthrosis 11.4
3 immunodeficiency, common variable, 8, with autoimmunity 11.3
4 thrombotic thrombocytopenic purpura, acquired 11.2
5 thrombocytopenia 10.7
6 antiphospholipid syndrome, familial 10.7
7 purpura 10.3
8 ectodermal dysplasia, ectrodactyly, and macular dystrophy 10.2 MPL THPO
9 thrombocytopenia, congenital amegakaryocytic 10.2 MPL THPO
10 cytokine receptor deficiency 10.2 GP1BA THPO
11 early-onset anterior polar cataract 10.1 MPL THPO
12 vcl-related dilated cardiomyopathy 10.1 GP1BA SELP
13 interstitial lung disease, nephrotic syndrome, and epidermolysis bullosa, congenital 10.1 ITGA2B ITGB3
14 granulomatous hepatitis 10.1 MPL SELP THPO
15 erythrocytosis, somatic 10.1 IFNA2 MPL THPO
16 neuromyelitis optica 10.0 IFNA2 MPL THPO
17 autoimmune hemolytic anemia 10.0
18 thunderclap headache 10.0 ITGA2B ITGB3
19 fetal macrosomia 10.0 GP1BA ITGA2B ITGB3
20 facial dysmorphism-anorexia-cachexia-eye and skin anomalies syndrome 10.0 GP1BA ITGA2B ITGB3
21 leukemia 10.0
22 stt3a-cdg and stt3b-cdg 10.0 GP6 ITGB3
23 essential thrombocythemia 10.0 GP1BA ITGA2B ITGB3
24 hemolytic anemia 10.0
25 spondylocostal dysostosis 2 10.0 IFNA2 MPL
26 malignant epithelial mesothelioma 10.0 GATA3 IFNA2
27 subclavian artery aneurysm 9.9 ITGA2B SELP
28 monocular exotropia 9.9 GP1BA GP6 ITGB3
29 gluten allergy 9.9 ITGA2B ITGB3 MPL THPO
30 atrophic nonflaccid tympanic membrane 9.9 GP1BA GP6 SELP
31 mental depression 9.9 ITGA2B MPL SELP THPO
32 pyridoxamine 5'-phosphate oxidase deficiency 9.8 GP1BA ITGA2B ITGB3 SELP
33 hyperparathyroidism, neonatal 9.8 GATA3 ITGA2B MPL THPO
34 haemonchiasis 9.8 GP1BA ITGA2B ITGB3 MPL THPO
35 perichondritis of auricle 9.8 GP1BA ITGA2B ITGB3 MPL THPO
36 tracheal disease 9.8 GP1BA ITGA2B ITGB3 MPL THPO
37 bone development disease 9.7 GP1BA GP6 ITGB3 SELP
38 thrombotic thrombocytopenic purpura 9.7
39 mixed connective tissue disease 9.7
40 evans' syndrome 9.7
41 fasciitis 9.7
42 cartilage-hair hypoplasia 9.7
43 eosinophilic fasciitis 9.7
44 autoimmune hepatitis 9.7
45 gastric cancer 9.7
46 myasthenia gravis 9.7
47 severe nonproliferative diabetic retinopathy 9.6 GP1BA ITGA2B ITGB3 MPL SELP THPO
48 ocular hyperemia 9.6 GP1BA ITGA2B ITGB3 MPL SELP THPO
49 myeloproliferative neoplasm 9.6 GP1BA ITGA2B ITGB3 MPL SELP THPO
50 immunodeficiency 21 9.6 GP1BA GP6 ITGA2B ITGB3 THPO

Graphical network of the top 20 diseases related to Thrombocytopenic Purpura, Autoimmune:



Diseases related to Thrombocytopenic Purpura, Autoimmune

Symptoms & Phenotypes for Thrombocytopenic Purpura, Autoimmune

Symptoms by clinical synopsis from OMIM:

188030

Clinical features from OMIM:

188030

Human phenotypes related to Thrombocytopenic Purpura, Autoimmune:

56 32 (show all 12)
id Description HPO Frequency Orphanet Frequency HPO Source Accession
1 thromboembolism 56 32 Very frequent (99-80%) HP:0001907
2 thrombocytopenia 56 32 Very frequent (99-80%) HP:0001873
3 purpura 56 32 Frequent (79-30%) HP:0000979
4 gastrointestinal hemorrhage 56 32 Occasional (29-5%) HP:0002239
5 epistaxis 56 32 Occasional (29-5%) HP:0000421
6 bruising susceptibility 56 32 Occasional (29-5%) HP:0000978
7 gingival bleeding 56 32 Occasional (29-5%) HP:0000225
8 petechiae 56 32 Frequent (79-30%) HP:0000967
9 arterial thrombosis 56 32 Frequent (79-30%) HP:0004420
10 cerebral hemorrhage 56 32 Very rare (<4-1%) HP:0001342
11 abnormal bleeding 32 HP:0001892
12 platelet antibody positive 32 HP:0003454

GenomeRNAi Phenotypes related to Thrombocytopenic Purpura, Autoimmune according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased human papilloma virus 16 (HPV16) pseudovirus infection GR00306-A 9.02 DNMT3B GATA3 GP6 IL18 ITGA2B

MGI Mouse Phenotypes related to Thrombocytopenic Purpura, Autoimmune:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10 DNMT3B GATA3 GP1BA GP6 IL18 ITGA2B
2 cellular MP:0005384 9.92 DNMT3B GATA3 GP1BA IL18 ITGA2B ITGB3
3 homeostasis/metabolism MP:0005376 9.81 GATA3 GP1BA GP6 IL18 ITGA2B ITGB3
4 immune system MP:0005387 9.65 LRBA MPL SELP THPO DNMT3B GATA3
5 vision/eye MP:0005391 9.1 DNMT3B GATA3 GP6 IL18 ITGB3 SELP

Drugs & Therapeutics for Thrombocytopenic Purpura, Autoimmune

Drugs for Thrombocytopenic Purpura, Autoimmune (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 903)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Amodiaquine Approved Phase 4 86-42-0 2165
2
Artemether Approved Phase 4,Phase 3 71963-77-4 119380 68911
3
Artesunate Approved Phase 4 88495-63-0 6917864 5464098
4
Lumefantrine Approved Phase 4,Phase 3 82186-77-4 6437380
5
Mefloquine Approved Phase 4 53230-10-7 4046
6
Alfentanil Approved, Illicit Phase 4 71195-58-9 51263
7
Methylprednisolone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 83-43-2 6741
8
Prednisolone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 50-24-8 5755
9
Estradiol Approved, Investigational, Vet_approved Phase 4,Phase 2 50-28-2 5757 53477783
10
Ethinyl Estradiol Approved Phase 4 57-63-6 5991
11
Moxifloxacin Approved, Investigational Phase 4 354812-41-2, 151096-09-2 152946
12
Norgestimate Approved Phase 4 35189-28-7 6540478
13
Pyrimethamine Approved, Vet_approved Phase 4,Phase 2 58-14-0 4993
14
Sulfadoxine Approved Phase 4,Phase 2 2447-57-6 17134
15
Pregabalin Approved, Illicit, Investigational Phase 4,Phase 3 148553-50-8 5486971
16
Valproic Acid Approved, Investigational Phase 4 99-66-1 3121
17
Amoxicillin Approved, Vet_approved Phase 4,Phase 2,Phase 3 26787-78-0 33613 2171
18
Clarithromycin Approved Phase 4,Phase 2,Phase 3,Phase 1 81103-11-9 84029
19
Lansoprazole Approved, Investigational Phase 4,Phase 2 103577-45-3 3883
20
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3 50-02-2 5743
21
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 53-03-2 5865
22
Zinc Approved Phase 4,Phase 3,Phase 2,Phase 1 7440-66-6 32051 23994
23
Bevacizumab Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 216974-75-3
24
rituximab Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 174722-31-7 10201696
25
Benzocaine Approved Phase 4,Phase 3,Phase 2 1994-09-7, 94-09-7 2337
26
Everolimus Approved Phase 4,Phase 3,Phase 2,Phase 1 159351-69-6 6442177
27
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 22916-47-8 4189
28
Sirolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 53123-88-9 5284616 6436030 46835353
29
Adalimumab Approved Phase 4,Phase 3 331731-18-1 16219006
30
Dinoprostone Approved Phase 4 363-24-6 5280360
31
Ketorolac Approved Phase 4 74103-06-3, 66635-83-4 3826
32
Nepafenac Approved Phase 4 78281-72-8 151075
33
Ezetimibe Approved Phase 4 163222-33-1 150311
34
Simvastatin Approved Phase 4,Phase 3,Phase 1,Phase 2 79902-63-9 54454
35
Citalopram Approved Phase 4,Phase 3 59729-33-8 2771
36
Lopinavir Approved Phase 4 192725-17-0 92727
37
Ritonavir Approved, Investigational Phase 4 155213-67-5 392622
38
Acetaminophen Approved Phase 4,Phase 3 103-90-2 1983
39
Pioglitazone Approved, Investigational Phase 4,Phase 2 111025-46-8 4829
40
Rosiglitazone Approved, Investigational Phase 4,Phase 1 122320-73-4 77999
41
Heparin Approved, Investigational Phase 4,Phase 3 9005-49-6 772 46507594
42
Acetylcysteine Approved, Investigational Phase 4 616-91-1 12035
43
Trimethoprim Approved, Vet_approved Phase 4 738-70-5 5578
44
Yohimbine Approved, Vet_approved Phase 4 146-48-5 8969
45
Imipramine Approved Phase 4 50-49-7 3696
46
Ranibizumab Approved Phase 4,Phase 3,Phase 2 347396-82-1 459903
47
Desipramine Approved Phase 4,Phase 2,Phase 1 50-47-5 2995
48
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1 51-61-6, 62-31-7 681
49
Methamphetamine Approved, Illicit Phase 4,Phase 2,Phase 1 537-46-2 10836
50
Labetalol Approved Phase 4 36894-69-6 3869

Interventional clinical trials:

(show top 50) (show all 1366)
id Name Status NCT ID Phase
1 Effectiveness of Artemisinin Combination Regimens in Falciparum Malaria Unknown status NCT00902811 Phase 4
2 Pain Evaluation During Follicle Aspiration: Comparison of Two Sedation Protocols Unknown status NCT00742807 Phase 4
3 Comparison of a Nutritional Anti-Inflammatory Treatment to Steroids for Pediatric Crohn's Disease - the Molecular Basis Unknown status NCT00265772 Phase 4
4 A Comparison of Prophylactic Antibacterial Efficacy of Besivance vs. VIGAMOX Prior to Cataract Surgery Unknown status NCT01296542 Phase 4
5 Aqueous Absorption and Pharmacokinetics of Besivance Versus VIGAMOX in Patients Undergoing Phacoemulsification Unknown status NCT01296191 Phase 4
6 Intermittent Antimalaria Treatment With SP in African Children Unknown status NCT00168948 Phase 4
7 tDCS as Add on Therapy for Treatment of Tobacco Dependence by Standardized Behaviour Therapy Unknown status NCT01729507 Phase 4
8 Efficacy and Safety of Amodiaquine and Amodiaquine-Artesunate Unknown status NCT00238017 Phase 4
9 Using Non-Fluoroscopic Imaging Devices to Decrease Radiation Exposure During Ablation of Supraventricular Tachycardia Unknown status NCT00979303 Phase 4
10 Effects of Pregabalin on Mechanical Hyperalgesia Unknown status NCT00310583 Phase 4
11 Pharmacogenomics of Mood Stabilizer Response in Bipolar Disorder (PGBD) Unknown status NCT01272531 Phase 4
12 Helicobacter Pylori Infection in Children With Chronic Idiopathic Thrombocytopenic Purpura Completed NCT00467571 Phase 4
13 Platelet Function in Idiopathic Thrombocytopenic Purpura (ITP) Patients With Eltrombopag Completed NCT00888901 Phase 4
14 A Safety Study of Intravenous Immunoglobulin in Patients With Chronic Immune Thrombocytopenic Purpura (ITP) Completed NCT01390649 Phase 4
15 Study on Bone Marrow Morphology in Adults Receiving Romiplostim for Treatment of Thrombocytopenia Associated With Immune Thrombocytopenia Purpura (ITP) Completed NCT00907478 Phase 4
16 High-dose Dexamethasone Versus Conventional Dose Prednisone for Initial Treatment of Primary Immune Thrombocytopenia (ITP) Completed NCT01356511 Phase 4
17 A Comparison of Prostaglandin E2 (PGE2) Inhibition of Acuvail(Ketorolac 0.45%), Xibrom (Bromfenac 0.09%)and Nevanac (Nepafenac)in Patients Undergoing Phacoemulsification Completed NCT01021761 Phase 4
18 A Comparison of Peak Aqueous Penetration of Acuvail (Ketorolac 0.45%), Xibrom (Bromfenac 0.09%), and Nevanac (Nepafenac 0.1%)in Patients Undergoing Phacoemulsification Completed NCT01001806 Phase 4
19 The PostprAndial eNdothelial Function After Combination of Ezetimibe and simvAstatin Study Completed NCT00817843 Phase 4
20 Comparison of Rotating vs. Fixed Platform of the COLUMBUS Knee Prosthesis Completed NCT00822640 Phase 4
21 Treatment of Depression in Adults Completed NCT00073697 Phase 4
22 Raltegravir Kaletra Pharmacokinetics Completed NCT00564772 Phase 4
23 Aqueous Concentrations and PGE2 Inhibition of Ketorolac 0.4% vs. Bromfenac 0.09% in Cataract Patients: Trough Drug Effects Completed NCT00469690 Phase 4
24 Paracetamol and Endothelial Function in Patients With Stable Coronary Artery Disease Completed NCT00534651 Phase 4
25 Miralax (PEG 3350) vs. Golytely as Bowel Preparation for Screening Colonoscopy Completed NCT01170754 Phase 4
26 A Comparison of Post Phacoemulsification Aqueous Flare in Patients Using Ketorolac 0.45% 2 Times Daily (BID) and Bromfenac 0.09% 2 Times Daily (BID) Completed NCT01023724 Phase 4
27 Effect of Thiazolidinedione Treatment Vascular Risk Markers Completed NCT00571506 Phase 4
28 Mechanism of Fatty Acid-induced Impairment of Glucose-simulated Insulin Secretion - Effect of Buphenyl Completed NCT00533559 Phase 4
29 Mechanism of Fatty Acid-Induced Impairment of Glucose-Stimulated Insulin Secretion Completed NCT00188773 Phase 4
30 A Longitudinal 2-year Bone Marrow Study of Eltrombopag in Previously Treated Adults, With Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP) Completed NCT01098487 Phase 4
31 Mechanism of Growth Hormone Effects on Adipose Tissue Completed NCT00453557 Phase 4
32 "TAKE TIME" Pioglitazone Reverses Defects in Mitochondrial Biogenesis in Patients With T2DM Completed NCT00402012 Phase 4
33 Moxifloxacin vs. Polytrim for Conjunctivitis Completed NCT00581542 Phase 4
34 Aqueous Concentrations and PGE2 Inhibition of Ketorolac 0.4% vs. Bromfenac 0.09% in Cataract Patients Completed NCT00347503 Phase 4
35 Effects of Comorbid Personality Disorder on the Treatment of Bipolar I Disorder Completed NCT00178061 Phase 4
36 Bioequivalence Study Comparing Two Test Products With One Reference Product, All Containing 5 mg Yohimbine Completed NCT00975325 Phase 4
37 Oat Breakfast Satiety Study Completed NCT01372683 Phase 4
38 Psychosocial Therapy Plus Maintenance Pharmacotherapy for Treating Bipolar Disorder Completed NCT00227968 Phase 4
39 Comparing Various Treatments for Achieving and Maintaining Remission of Depression Completed NCT00227955 Phase 4
40 VEGF-antagonism and Endothelial Function in Age-related Macular Degeneration (AMD) Completed NCT00727753 Phase 4
41 Methamphetamine Abuse Treatment in Patients With AIDS - 1 Completed NCT00000321 Phase 4
42 Pharmacokinetic Study of Topically Applied Veregen 15% Compared With Oral Intake of Green Tea Beverage Completed NCT01082302 Phase 4
43 Standard Open Surgery Versus Endovascular Repair of Abdominal Aortic Aneurysm (AAA) Completed NCT00094575 Phase 4
44 Xpert MTB/Rif, a New Tool for the Diagnosis of Pulmonary Tuberculosis in Two Municipalities in Brazil Completed NCT01363765 Phase 4
45 Effects of Ezetimibe on Postprandial Hyperlipidemia and Endothelial Function Completed NCT00189085 Phase 4
46 Is Omega-3 Fatty Acid Red Blood Cell (RBC) Saturation Product Dependent? Completed NCT01091714 Phase 4
47 Depression: The Search for Treatment-Relevant Phenotypes-Pilot Study Completed NCT00222820 Phase 4
48 Dry Age-Related Macular Degeneration (AMD) Treatment With Rheopheresis Trial Completed NCT00751361 Phase 4
49 Cryoplasty CLIMB-registry Completed NCT00459888 Phase 4
50 CAFE Study - Cancer Patient Fracture Evaluation Completed NCT00211237 Phase 4

Search NIH Clinical Center for Thrombocytopenic Purpura, Autoimmune

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cochrane evidence based reviews: purpura, thrombocytopenic, idiopathic

Genetic Tests for Thrombocytopenic Purpura, Autoimmune

Genetic tests related to Thrombocytopenic Purpura, Autoimmune:

id Genetic test Affiliating Genes
1 Idiopathic Thrombocytopenic Purpura 29

Anatomical Context for Thrombocytopenic Purpura, Autoimmune

MalaCards organs/tissues related to Thrombocytopenic Purpura, Autoimmune:

39
Bone, Skin, Bone Marrow

Publications for Thrombocytopenic Purpura, Autoimmune

Articles related to Thrombocytopenic Purpura, Autoimmune:

id Title Authors Year
1
Autoimmune thrombocytopenic purpura, autoimmune hemolytic anemia and gastric cancer appeared in a patient with myasthenia gravis. ( 16679706 )
2006
2
Rituximab for immune cytopenia in adults: idiopathic thrombocytopenic purpura, autoimmune hemolytic anemia, and Evans syndrome. ( 14601692 )
2003
3
Eosinophilic fasciitis following idiopathic thrombocytopenic purpura, autoimmune hemolytic anemia and Hashimoto's disease. ( 10592421 )
1999
4
Cartilage hair hypoplasia with thrombocytopenic purpura, autoimmune haemolytic anaemia and cell-mediated immunodeficiency. ( 3950893 )
1986

Variations for Thrombocytopenic Purpura, Autoimmune

Copy number variations for Thrombocytopenic Purpura, Autoimmune from CNVD:

7
id CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 21699 1 160500000 165500000 Copy number FCGR2C Idiopathic thrombocytopenic purpura
2 46119 10 77700000 82000000 Copy number BMPR1A Idiopathic thrombocytopenic purpura
3 121460 18 43500000 48200000 Copy number MADH4 Idiopathic thrombocytopenic purpura

Expression for Thrombocytopenic Purpura, Autoimmune

Search GEO for disease gene expression data for Thrombocytopenic Purpura, Autoimmune.

Pathways for Thrombocytopenic Purpura, Autoimmune

Pathways related to Thrombocytopenic Purpura, Autoimmune according to GeneCards Suite gene sharing:

(show all 15)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
12.69 GATA3 GP1BA GP6 IFNA2 ITGA2B ITGB3
2
Show member pathways
11.95 GP6 ITGB3 SELP
3 11.94 FCGR2C IFNA2 IL18
4
Show member pathways
11.91 IFNA2 MPL THPO
5
Show member pathways
11.85 GP1BA GP6 ITGA2B ITGB3
6 11.71 GP1BA GP6 ITGA2B ITGB3
7 11.54 GP1BA ITGA2B ITGB3 THPO
8
Show member pathways
11.54 GP1BA ITGA2B ITGB3 MPL THPO
9 11.29 GP6 ITGA2B ITGB3
10 11.17 GP1BA IFNA2 ITGA2B ITGB3 MPL THPO
11 11.08 ITGA2B ITGB3
12 11.04 GATA3 IL18
13 10.91 ITGA2B ITGB3
14 10.78 ITGA2B ITGB3
15 10.55 GP1BA GP6

GO Terms for Thrombocytopenic Purpura, Autoimmune

Cellular components related to Thrombocytopenic Purpura, Autoimmune according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 integral component of plasma membrane GO:0005887 9.63 GP1BA GP6 ITGA2B ITGB3 MPL SELP
2 cell surface GO:0009986 9.35 GP1BA GP6 ITGA2B ITGB3 MPL
3 integrin complex GO:0008305 9.26 ITGA2B ITGB3
4 platelet alpha granule membrane GO:0031092 8.8 ITGA2B ITGB3 SELP

Biological processes related to Thrombocytopenic Purpura, Autoimmune according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 cytokine-mediated signaling pathway GO:0019221 9.61 GP1BA IFNA2 MPL
2 platelet degranulation GO:0002576 9.58 ITGA2B ITGB3 SELP
3 platelet activation GO:0030168 9.54 GP1BA GP6 ITGB3
4 positive regulation of tyrosine phosphorylation of Stat3 protein GO:0042517 9.46 IFNA2 IL18
5 positive regulation of protein kinase B signaling GO:0051897 9.43 GATA3 IL18 THPO
6 platelet aggregation GO:0070527 9.33 GP1BA ITGA2B ITGB3
7 positive regulation of leukocyte migration GO:0002687 9.32 ITGA2B SELP
8 blood coagulation GO:0007596 9.02 GATA3 GP1BA GP6 IFNA2 ITGB3
9 thrombopoietin-mediated signaling pathway GO:0038163 8.96 MPL THPO

Molecular functions related to Thrombocytopenic Purpura, Autoimmune according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular matrix binding GO:0050840 8.62 ITGA2B ITGB3

Sources for Thrombocytopenic Purpura, Autoimmune

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....